Predictive modeling estimated that a 25% reduction in pNfLc, similar to that observed with ozanimod 0.92 mg, predicts an ARR (standard error [SE]) of 0.18-0.23 (0.4), whereas a 13% reduction, similar to IFN, predicts an ARR (SE) of 0.29-0.37 (0.04). Conclusion Our findings support pNfL-c as a biomarker for relapsing MS disease activity. Ozanimod caused greater dosedependent reductions in pNfL-c and ARR than IFN.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.